Marissa N. Balak - Concepedia

Concepedia

Author

Marissa N. Balak

Memorial Sloan Kettering Cancer Center

Also Known As

Marissa Balak, Marissa N. Balak

37

Publications

3.9K

Citations

10

H-Index

41

Concepts

All Affiliations

Memorial Sloan Kettering Cancer Center Cornell University The University of Texas Southwestern Medical Center Novartis (Switzerland)

MN

About

Marissa N. Balak is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, oncology, and tumor biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	2.3K
2	Engineering	2	2	2.1K
3	Cell Biology	2	2	592
4	Health Sciences	1	1	22
5	Applied Physiology	1	1	22

Marissa N. Balak

×

10

Publications

3.9K

Citations

10

H-Index

	Year	Citations
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib James Bean, Cameron Brennan, Jin‐Yuan Shih, Proceedings of the National Academy of Sciences Harbors Met AmplificationEngineeringPathologyTumor BiologyOncology	2007	1.6K
Novel D761Y and Common Secondary T790M Mutations in Epidermal Growth Factor Receptor–Mutant Lung Adenocarcinomas with Acquired Resistance to Kinase Inhibitors Marissa N. Balak, Yixuan Gong, Gregory J. Riely, Clinical Cancer Research	2006	824
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding Hyo-Eun Carrie Bhang, David A. Ruddy, Viveksagar Krishnamurthy Radhakrishna, Nature Medicine High-complexity BarcodingTumor BiologyCancer TherapySystems BiologyEngineering	2015	513
Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas Yixuan Gong, Romel Somwar, Katerina Politi, PLoS Medicine	2007	312
Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors Associated with a Novel T854A Mutation in a Patient with <i>EGFR</i>-Mutant Lung Adenocarcinoma James Bean, Gregory J. Riely, Marissa N. Balak, Clinical Cancer Research	2008	276
Development of New Mouse Lung Tumor Models Expressing EGFR T790M Mutants Associated with Clinical Resistance to Kinase Inhibitors Lucía Regales, Marissa N. Balak, Yixuan Gong, PLoS ONE	2007	124
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib James Bean, Cameron Brennan, Jin-Yuan Shih, Molecular Cancer Therapeutics Pr-10 Somatic MutationsKinase InhibitorsPathologyTumor BiologyMolecular Diagnostics	2007	121
Loss of Tuberous Sclerosis Complex 2 (TSC2) Is Frequent in Hepatocellular Carcinoma and Predicts Response to mTORC1 Inhibitor Everolimus Hung Huynh, Huai-Xiang Hao, Stephen L. Chan, Molecular Cancer Therapeutics PathologyCancer BiologyTumor BiologyHcc PatientsPredicts Response	2015	79
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity Kelli‐Ann Monaco, Ping Wang, Marissa N. Balak, Molecular Cancer Research	2017	25
Enhanced Motor Function by Training in Spinal Cord Contused Rats Following Radiation Therapy Ronaldo M. Ichiyama, Melissa Potuzak, Marissa N. Balak, PLoS ONE Enhanced Motor FunctionMotor ControlThoracic SpineSpinal DisorderOrthopaedic Surgery	2009	22

Page 1